Search Result

Results for "

MTD

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aminopeptidase (1) Apoptosis (3) COX (1) DNA Methyltransferase (1) Folate Receptor (FR) (1) Isotope-Labeled Compounds (1) NF-κB (1) Peptide-Drug Conjugates (PDCs) (3) Small Interfering RNA (siRNA) (2) Topoisomerase (1) TRP Channel (1)
By Research Areas:	Cancer (7) Inflammation/Immunology (1)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131503

13-Methyltetradecanoic acid 13-MTD; 13-Methylmyristic acid	Apoptosis	Cancer
13-Methyltetradecanoic acid (13-MTD), a saturated branched-chain fatty acid with potent anticancer effects. 13-Methyltetradecanoic acid induces apoptosis in many types of human cancer cells .

HY-161402

METTL16-IN-1	DNA Methyltransferase	Cancer
METTL16-IN-1 is a potent METTL16 inhibitor with an IC₅₀ value of 1.7 μM and a K_d value of 1.35 μM. Mettl16-in-1 inhibits the binding interaction of U6 snRNA deletion and METTL16 MTD with an IC₅₀ value of 2.5 μM. METTL16-IN-1 has antitumor activity .

HY-15491

AG-024322	COX Apoptosis	Cancer
AG-024322 is a potent ATP-competitive pan-CDK inhibitor against cell cycle kinases CDK1, CDK2, and CDK4 with K_i values in the 1-3 nM range . AG-024322 displays broad-spectrum anti-tumor activity and clear target modulation in vivo. AG-024322 induces cell apoptosis .

HY-155998

NF-κB-IN-11	NF-κB	Inflammation/Immunology
NF-κB-IN-11 (Compound 3i) is a NF-κB inhibitor. NF-κB-IN-11 inhibits TNF-α induced activation of NF-κB pathway, and inhibits nuclear translocation of NF-κB. NF-κB-IN-11 down-regulates the expression levels of phosphor-IKK, IκBα, and NF-κB p65. NF-κB-IN-11 has anti-inflammatory activity, and alleviates dextran sulfate sodium-induced colitis in mice. NF-κB-IN-11 (p.o.) shows a MTD more than 1852 mg/kg in mice acute toxicity assay .

HY-131503S

13-Methyltetradecanoic acid-d6 13-MTD-d₆; 13-Methylmyristic acid-d₆	Isotope-Labeled Compounds Apoptosis	Cancer
13-Methyltetradecanoic acid-d6 is a deuterated labeled 13-Methyltetradecanoic acid . 13-Methyltetradecanoic acid (13-MTD), a saturated branched-chain fatty acid with potent anticancer effects. 13-Methyltetradecanoic acid induces apoptosis in many types of human cancer cells .

HY-RS18323

Bok Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Bok Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bok gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Bok Mouse Pre-designed siRNA Set A Bok Mouse Pre-designed siRNA Set A

HY-RS08737

MT1E Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MT1E Human Pre-designed siRNA Set A contains three designed siRNAs for MT1E gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MT1E Human Pre-designed siRNA Set A MT1E Human Pre-designed siRNA Set A

HY-P10762

CBP-1008 LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
CBP-1008 is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. CBP-1008 binds to FRα with high affinity and TRPV6 with low affinity. CBP-1008 has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

HY-P10765

DTS-108	Peptide-Drug Conjugates (PDCs) Topoisomerase	Cancer
DTS-108 is a prodrug of SN38 (HY-13704) (a Topoisomerase I inhibitor). DTS-108 is a conjugate generated by linking SN38 to a human oligopeptide via an esterase sensitive cross-linker. DTS-108 exhibits anti-tumor activity against colorectal, lung, and mammary cancer .

HY-P10759

DTS-201 sodium	Peptide-Drug Conjugates (PDCs) Aminopeptidase	Cancer
DTS-201 sodium (CPI-0004Na) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer .

Cat. No.	Product Name	Target	Research Area